Wells Fargo & Company MN Acquires 14,460 Shares of AdaptHealth Corp. (NASDAQ:AHCO)

Wells Fargo & Company MN increased its holdings in AdaptHealth Corp. (NASDAQ:AHCO) by 36.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,546 shares of the company’s stock after acquiring an additional 14,460 shares during the quarter. Wells Fargo & Company MN’s holdings in AdaptHealth were worth $519,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Barclays PLC lifted its position in shares of AdaptHealth by 361.3% in the 3rd quarter. Barclays PLC now owns 181,240 shares of the company’s stock worth $2,034,000 after purchasing an additional 141,949 shares during the period. JPMorgan Chase & Co. raised its stake in AdaptHealth by 73.2% in the third quarter. JPMorgan Chase & Co. now owns 191,833 shares of the company’s stock worth $2,154,000 after buying an additional 81,097 shares in the last quarter. Reinhart Partners LLC. lifted its holdings in AdaptHealth by 1.1% in the fourth quarter. Reinhart Partners LLC. now owns 6,266,854 shares of the company’s stock worth $59,660,000 after buying an additional 68,212 shares during the period. Proficio Capital Partners LLC bought a new stake in AdaptHealth during the 4th quarter valued at approximately $181,000. Finally, Pacer Advisors Inc. purchased a new position in shares of AdaptHealth during the 4th quarter worth approximately $76,271,000. Institutional investors own 82.67% of the company’s stock.

AdaptHealth Price Performance

AHCO opened at $8.78 on Friday. The firm has a market cap of $1.18 billion, a PE ratio of -5.32, a P/E/G ratio of 1.08 and a beta of 1.64. The stock has a 50-day moving average price of $9.53 and a 200-day moving average price of $9.81. AdaptHealth Corp. has a 1 year low of $7.11 and a 1 year high of $11.90. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.24 and a quick ratio of 1.00.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AHCO. Royal Bank of Canada raised their target price on AdaptHealth from $11.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, February 26th. Robert W. Baird boosted their target price on shares of AdaptHealth from $14.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. UBS Group decreased their price target on shares of AdaptHealth from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Truist Financial boosted their price objective on shares of AdaptHealth from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. Finally, Canaccord Genuity Group raised their target price on shares of AdaptHealth from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AdaptHealth has a consensus rating of “Buy” and a consensus target price of $13.80.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.